Paradigm Diagnostics is a technology company.
Paradigm Diagnostics has raised $15.0M across 1 funding round.
Paradigm Diagnostics has raised $15.0M in total across 1 funding round.
Paradigm Diagnostics is a molecular diagnostics company that developed the Paradigm Cancer Diagnostic (PCDx) test, a next-generation sequencing-based genomic profiling tool for patients with advanced, refractory, or recurrent cancer.[1][2][4] It serves oncologists and cancer patients by providing comprehensive molecular profiling, including genome genetic testing and oncology genetic testing, to guide targeted therapies and clinical trial recommendations with smaller sample requirements and faster results than competitors.[1][4] The company, headquartered in Phoenix, Arizona, was founded around 2012-2016, raised $14.4M in funding, and was acquired by Exact Sciences in March 2020, enhancing Exact Sciences' advanced cancer diagnostics portfolio.[1][2][3][4]
Paradigm Diagnostics emerged as a molecular information corporation focused on bringing comprehensive cancer genomic profiling to physicians and patients, addressing gaps in personalized cancer treatment.[2] Founded in 2012 (with some sources noting 2016), it was based in Phoenix at 445 N. 5th Street and quickly advanced its PCDx test, which gained Medicare coverage under Palmetto GBA's MolDx program for next-generation sequencing in solid tumors.[2][4] A pivotal moment came in March 2020 when Exact Sciences acquired it alongside Viomics, integrating Paradigm's scalable clinical lab and therapy selection test into a larger precision oncology platform.[3][4]
Paradigm Diagnostics rode the wave of precision oncology, a trend accelerating in the 2010s toward genomic profiling to personalize cancer care amid rising demands for targeted therapies and immunotherapy.[2][4] Its timing aligned with expanding Medicare coverage for next-generation sequencing tests, reducing barriers for advanced cancer patients and influencing adoption in clinical practice.[4] Market forces like smaller biopsy needs and faster turnaround addressed pain points in tumor profiling, while its acquisition by Exact Sciences amplified impact by merging with established platforms like Cologuard and Oncotype DX, strengthening the ecosystem for end-to-end cancer diagnostics from screening to late-stage therapy selection.[4]
Post-2020 acquisition, Paradigm's PCDx test and team continue evolving within Exact Sciences, likely expanding through commercial scaling, deeper AI integration in biomarker discovery, and broader payer coverage amid growing precision medicine demand.[3][4] Trends like multi-omics profiling and liquid biopsies will shape its trajectory, potentially enhancing therapy matching for rarer cancers. Its influence may grow by powering Exact Sciences' push into deadlier malignancies, solidifying leadership in actionable cancer insights and tying back to its core mission of smarter, faster patient answers.[4]
Paradigm Diagnostics has raised $15.0M in total across 1 funding round.
Paradigm Diagnostics's investors include BlueStone Venture Partners.
Paradigm Diagnostics has raised $15.0M across 1 funding round. Most recently, it raised $15.0M Series B in May 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2019 | $15.0M Series B | BlueStone Venture Partners |